Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

How could emerging technologies impact cancer care?

The major innovations in cancer diagnosis, therapy/palliative care and surgical intervention are too numerous to list here. But enormous strides have taken place in stem cell therapy, monoclonal antibody therapy and genetic screening.

17 Oct 2016

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis announced today that the US Food and Drug Administration has granted three simultaneous approvals for the expanded use of Ilaris (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes.

24 Sep 2016

Mayo Clinic article provides better understanding on potentially devastating liver disease

An article published today in the New England Journal of Medicine updates the medical community on a potentially devastating liver disease that afflicts approximately 29,000 Americans.

22 Sep 2016

Novel Trojan Horse antibody strategy may target Ebola's Achilles' heel

In research published online today in Science, a team of scientists describe a new therapeutic strategy to target a hidden Achilles' heel shared by all known types of Ebola virus.

8 Sep 2016

Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Two studies appearing in the September 6 issue of JAMA examine the effectiveness of nasal sprays to reduce the frequency and duration of nosebleeds caused by hereditary hemorrhagic telangiectasia (HHT), an inherited condition characterized by abnormal blood vessels which are delicate and prone to bleeding.

6 Sep 2016

Added benefit not proven for new combination therapy in multiple myeloma

The monoclonal antibody elotuzumab has been approved in combination with lenalidomide and dexamethasone since May 2016 for further treatment of multiple myeloma in adults who have received at least one previous treatment.

1 Sep 2016

Monoclonal antibody removes brain amyloid plaques in patients with Alzheimer's disease

Scientists at Neurimmune today described results from the Phase 1b PRIME clinical trial of the monoclonal antibody aducanumab.

1 Sep 2016

LJI researchers reveal unanticipated way by which neutrophils defend against invading pathogens

As an arm of the innate immune system, white blood cells called neutrophils form the first line of defense against invading pathogens.

31 Aug 2016

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy.

19 Aug 2016

Added benefit not proven for orphan drug in treatment of adults with stomach cancer

Ramucirumab (trade name: Cyramza) is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours.

19 Aug 2016

New NIST Standard Reference Material helps ensure accurate measurements of HER2 breast cancer gene

A new measurement standard developed by the National Institute of Standards of Technology has been used successfully by the Frederick National Laboratory for Cancer Research to check the performance of next-generation DNA-sequencing technologies for evaluating gene variations associated with an increased risk of breast cancer.

18 Aug 2016

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with advanced renal cell cancer who have already undergone prior therapy.

11 Aug 2016

CTCA at Western begins clinical trial for novel antibody to treat patients with advanced tumors

Cancer Treatment Centers of America at Western Regional Medical Center has dosed its first three patients as part of the launch of a Phase I clinical trial using a novel antibody to treat patients with advanced solid tumors.

8 Aug 2016

Immunotherapy innovations in oncology: an interview with Robert LaCaze

The body’s immune system is an excellent weapon against many diseases. For more than 100 years, immunology and immunotherapy have played an ever-increasing role in the understanding and treatment of cancer.

8 Aug 2016

Scientists engineer therapeutic system with two arms to get better hold on cancer target

Scientists have engineered a sort of biological barbell that can get inside cancer cells and do damage to two proteins that work independently and together to enable cancer's survival and spread.

3 Aug 2016

Advances in head and neck cancer treatments: an interview with Prof. Argiris

Patients with head and neck cancer usually present with locally advanced disease and often require more than one type of treatment, which may include surgery, radiotherapy, and chemotherapy.

3 Aug 2016

Novel conjugate therapy shows promise in destroying ALL cells with few side effects

Researchers at UC Davis and Ionis Pharmaceuticals have developed a hybrid treatment that harnesses a monoclonal antibody to deliver antisense DNA to acute lymphoblastic leukemia (ALL) cells and that may lead to less toxic treatments for the disease.

29 Jul 2016

Texas Biomed scientists receive $23 million NIH grant to develop AIDS vaccine

To support a coordinated, innovative approach to the development of an AIDS vaccine, Texas Biomedical Research Institute scientists, together with a multi-institutional coalition of experts from the United States and Europe, have received a grant for $23 million from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

22 Jul 2016

Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding a novel monoclonal antibody therapy to traditional chemotherapy increased median survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer.

21 Jul 2016

Researchers develop antibody with potential therapeutic effects against multiple sclerosis

Inserm Unit U919, directed by Prof. Denis Vivien has developed an antibody with potential therapeutic effects against multiple sclerosis.

20 Jul 2016

Monoclonal Antibody News and Research

Further Reading

How could emerging technologies impact cancer care?

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Mayo Clinic article provides better understanding on potentially devastating liver disease

Novel Trojan Horse antibody strategy may target Ebola's Achilles' heel

Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Added benefit not proven for new combination therapy in multiple myeloma

Monoclonal antibody removes brain amyloid plaques in patients with Alzheimer's disease

LJI researchers reveal unanticipated way by which neutrophils defend against invading pathogens

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Added benefit not proven for orphan drug in treatment of adults with stomach cancer

New NIST Standard Reference Material helps ensure accurate measurements of HER2 breast cancer gene

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

CTCA at Western begins clinical trial for novel antibody to treat patients with advanced tumors

Immunotherapy innovations in oncology: an interview with Robert LaCaze

Scientists engineer therapeutic system with two arms to get better hold on cancer target

Advances in head and neck cancer treatments: an interview with Prof. Argiris

Novel conjugate therapy shows promise in destroying ALL cells with few side effects

Texas Biomed scientists receive $23 million NIH grant to develop AIDS vaccine

Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Researchers develop antibody with potential therapeutic effects against multiple sclerosis

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®